金城医药：子公司收到乳糖酸红霉素化学原料药上市申请批准通知书

Core Viewpoint - Jincheng Pharmaceutical announced the approval of a marketing application for its subsidiary's erythromycin lactobionate chemical raw material, indicating a significant advancement in its product portfolio and potential for treating serious infectious diseases [1] Group 1 - The approved product is an injectable form of erythromycin lactobionate, classified as a macrolide antibiotic [1] - This antibiotic is specifically used for the treatment of severe infectious diseases, highlighting its importance in the pharmaceutical market [1]